Drawing First Blood

Drawing First Blood

Two experts to debate controversial topics in hematology and health care.

To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug...

Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...

FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this...

Optimal Timing of Transplant in Myeloma

New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront...

Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these...

For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen...

Is Fludarabine Dead in CLL?

A few short years ago, fludarabine was considered the gold standard of front-line treatment for chronic lymphocytic leukemia (CLL), providing better response rates than...

Rituximab or Splenectomy in Steroid-Resistant ITP Patients?

Corticosteroids are the standard initial treatment for adult patients with idiopathic thrombocytopenic purpura (ITP), while splenectomy is considered second-line treatment. Drugs like rituximab have...

To Transplant or Not To Transplant in First Remission?

Most patients with newly diagnosed acute myeloid leukemia (AML) will achieve a first complete remission with standard induction chemotherapy. Durable remission or cure can only be attained, though, with further treatment...

Is There Still a Need for Radiation Therapy in Hodgkin Lymphoma?

The standard treatment for certain types of Hodgkin lymphoma is combined modality therapy – consisting of chemotherapy followed by radiation therapy. Recently, there has...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.